Department of Hematology, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), Accelerator Project, Centro de Investigación Biomédica en Red-Cáncer (CIBERONC) CB16/12/00369 and Center for Cancer Research-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, Salamanca 37007, Spain; Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Department of Hematology, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), Accelerator Project, Centro de Investigación Biomédica en Red-Cáncer (CIBERONC) CB16/12/00369 and Center for Cancer Research-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, Salamanca 37007, Spain; Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Hematol Oncol Clin North Am. 2023 Aug;37(4):727-749. doi: 10.1016/j.hoc.2023.04.006. Epub 2023 May 26.
Waldenström's macroglobulinemia (WM) is an immunoglobulin M monoclonal gammopathy produced by a bone marrow lymphoplasmacytic lymphoma, an indolent non-Hodgkin lymphoma in which the cure is still an unmet challenge. Combinations with alkylating agents, purine analogs, and monoclonal antibodies, Bruton tyrosine kinase, and proteasome inhibitors are used for the treatment of relapsed and refractory patients. Moreover, new additional agents can be seen on the horizon as potential effective therapies. No consensus on a preferred treatment in the relapsed setting is available yet.
华氏巨球蛋白血症（WM）是一种由骨髓淋巴浆细胞淋巴瘤产生的免疫球蛋白 M 单克隆丙种球蛋白病，是一种惰性非霍奇金淋巴瘤，其治愈仍然是一个未满足的挑战。烷化剂、嘌呤类似物和单克隆抗体、布鲁顿酪氨酸激酶和蛋白酶体抑制剂的联合应用用于治疗复发和难治性患者。此外，新的附加药物也可以在治疗领域中看到作为潜在有效的治疗方法。在复发环境中，还没有关于首选治疗方法的共识。
